KAIST RNA Therapy Blocks Brainstem Receptor to Stop Cancer Muscle Wasting

Researchers from KAIST and its faculty startup, Thor Therapeutics, have developed an RNA-based therapy that targets the neurological root of cancer cachexia. The treatment aims to stop the debilitating muscle and fat loss that affects a vast majority of cancer patients.

According to findings published in Cell Reports Medicine on July 27, 2026, the team utilized antisense oligonucleotides (ASOs) to silence the GFRAL receptor located in the brainstem. This receptor normally receives signals from the protein GDF15, which triggers the body's wasting response. By suppressing the production of GFRAL, the therapy effectively blocks the "receiver" of the wasting signal, preventing the metabolic decline associated with the syndrome.

The Challenge of Cachexia

Cancer cachexia is a complex wasting syndrome that affects an estimated 50% to 80% of all cancer patients. Unlike simple malnutrition, cachexia causes severe muscle and fat loss regardless of a patient's food intake. This physical decline often forces the discontinuation of chemotherapy, as patients become too frail to tolerate the treatment. Historically, medical interventions have focused on appetite stimulation, but these methods fail to address the underlying metabolic dysfunction driving the weight loss.

Preclinical Breakthroughs

In preclinical trials involving tumor-bearing mice, the GFRAL-silencing therapy demonstrated a dramatic impact on longevity and physical preservation. The research team specifically tested the treatment on mice where cachexia had already progressed. By day 50 of the study, the treated group showed a 90% survival rate, compared to just 20% in the untreated control group. The therapy significantly reduced muscle loss, suggesting that the metabolic wasting process can be interrupted even after it has begun.

Industry Implications

This shift in focus from the body's periphery to the brainstem represents a fundamental change in how wasting syndromes are treated. Professor Minho Shong noted that while existing therapies have only temporarily boosted appetite, this study is significant because it directly targets a key receptor in the brainstem at the RNA level to suppress the root cause of the condition.

If successfully translated to human clinical trials, this approach could serve as a next-generation adjuvant therapy. By preserving muscle mass and metabolic function, the treatment could improve the quality of life and increase the tolerance for aggressive cancer treatments, potentially raising overall survival rates for millions of patients.

Future Outlook

While the results in mice are stark, the next phase of development will focus on the transition to human subjects. Researchers will need to determine the optimal dosing and delivery mechanisms for ASOs in humans to ensure the GFRAL receptor is effectively silenced without off-target effects. For now, the study provides a verified molecular blueprint for treating one of oncology's most difficult-to-manage side effects.